Abstract
We describe two cases of rheumatoid arthritis (RA) patients and concomitant hepatitis C virus infection (HCV), treated with cyclosporine A (CsA) and anti-TNF-α agents. SGOT/SGPT and HCV-RNA serum levels remained unchanged longer than 1 year of treatment. No side effects were registered. We suggest that combination therapy with CsA and TNF-α blockers should be considered safe and well-tolerated in the treatment of HCV-positive RA patients.
References
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintman G; LIS2T Study Group (2004) Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplant Proc 77:1632–1638
Casanovas Taltavull T (2004) Impact of Cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 36:S291–S294
Nakamuta M, Kohjima M, Fukushima M, Morizono S, Kotoh K, Kobayashi N, Enjoji M (2005) Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc 37:4598–4602
Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M (2003) Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 38:567–572
Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282–1288
Galeazzi M, Bellisai F, Manganelli S, Morozzi G, Sebastiani GD (2006) Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 5(7):493–498
Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013–3022
Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082
Duvoux C, Mennecier D, Pageaux G (2002) Immunosuppression with tacrolimus and absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus graft reinfection. In: International Society of Transplantation Congress, abstract no. 2652
McCaughan GW (2004) Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 78:1413–1414
Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M (2005) Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129:1031–1041
Miura H, Itoh Y, Matsumoto Y, Tani M, Tanabe N, Isonokami M, Kurachi K, Kozuka T (1999) Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 38:310–314
Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, Singer MV, Rossol S (1998) Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269–277
Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY (1997) Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 42:2487–2494
Fukuda R, Ishimura N, Ishihara S, Chowdhury A, Morlyama N, Nogami C, Miyake T, Niigaki M, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S (1996) Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 16:390–399
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bellisai, F., Giannitti, C., Donvito, A. et al. Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 26, 1127–1129 (2007). https://doi.org/10.1007/s10067-006-0412-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0412-1